Does ajovy require a loading dose for first time users?

Does ajovy require a loading dose for first time users?

Ajovy does not require a loading dose. The recommended starting dose is 225 mg injected subcutaneously once monthly or 675 mg every three months, with no initial higher dose or loading phase required.

How does Ajovy dosing compare to other CGRP inhibitors?

Ajovy, fremanezumab, maintains consistent dosing from the first injection onward. Other CGRP inhibitors such as erenumab (Aimovig) and galcanezumab (Emgality) also avoid loading doses, but galcanezumab starts at 240 mg for the first month before switching to 120 mg monthly. Galcanezumab differs from Ajovy in its temporary initial boost, which has no clinical benefit over steady-state dosing.

Can patients self-administer Ajovy at home?

Patients can self-administer Ajovy after proper training. The drug comes in a prefilled syringe or autoinjector pen, which users receive after demonstration by a healthcare provider. This is similar to other monoclonal antibody treatments for migraine prevention.

When does Ajovy patent expire?

Ajovy’s core patent family covering the antibody itself is linked to US 7,943,125, which expires in 2028. Core compound patents expire in 2028. Extension possibilities exist through pediatric exclusivity or other mechanisms.

DrugPatentWatch.com